IP Library Granted Patent US 9,327,016
Granted Patent B2
US 9,327,016 · App. 14/378,190 · Granted May 3, 2016

Enzymes and methods for cleaving N-glycans from glycoproteins

Inventors: Daniel Garrido (Santiago, CL); J. Bruce German (Davis, CA); Carlito B. Lebrilla (Davis, CA); David A. Mills (Davis, CA)
Assignee: The Regents of the University of California
A61K38/47A23C9/1216A23L1/3058A23L2/52A61K31/715A61K35/741C12N9/2402C12N9/2497C12P19/04C12P21/005A61K38/00Y02P20/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,327,016
App. No.
14/378,190
Granted
May 3, 2016
Kind
B2
Abstract

Provided herein are deglycosylating enzymes that remove a broad range of N-glycans from N-glycosylated proteins. Further provided are methods of recombinantly producing and expressing the deglycosylating enzymes. The presently described deglycosylating enzymes can be used to produce free glycans for characterization, and for prebiotic and immunostimulatory uses. In addition, the presently described deglycosylating enzymes can be used to produce deglycosylated proteins for characterization, to improve digestion, and to reduce immunogenicity.

Claims (22)

1. A method of increasing the efficiency of protein digestion in an individual, comprising administering a pharmaceutical composition comprising a recombinant polypeptide comprising a sequence at least 90% identical to SEQ ID NO:5, wherein the polypeptide can cleave high mannose, complex, and hybrid N-glycans from a glycoprotein, and wherein the polypeptide lacks a transmembrane domain to the individual, thereby increasing the efficiency of protein digestion in the individual.

2. The method of claim 1 , wherein the individual is an infant.

3. A method of inducing satiety in an individual, comprising administering a pharmaceutical composition comprising a recombinant polypeptide comprising a sequence at least 90% identical to SEQ ID NO:5, wherein the polypeptide can cleave high mannose, complex, and hybrid N-glycans from a glycoprotein, and wherein the polypeptide lacks a transmembrane domain to the individual, thereby inducing satiety in the individual.

4. A method of deglycosylating a glycoprotein comprising a high mannose, complex, or hybrid N-glycan, the method comprising

contacting the glycoprotein with a polypeptide comprising a sequence at least 90% identical to SEQ ID NO:5, wherein the polypeptide lacks a transmembrane domain, thereby deglycosylating the glycoprotein and generating deglycosylated protein and free glycans.

5. A method of recombinantly producing a polypeptide, wherein said polypeptide comprises a sequence at least 90% identical to SEQ ID NO:5,

wherein said polypeptide can cleave high mannose, complex, and hybrid N-glycans from a glycoprotein,

the method comprising culturing a cell comprising a recombinant polynucleotide encoding the polypeptide comprising a sequence at least 90% identical to SEQ ID NO:5 under conditions appropriate for expression of the polypeptide, and

contacting the polypeptide with a glycoprotein comprising a high mannose, complex, or hybrid N-glycan, thereby deglycosylating the glycoprotein, thereby recombinantly producing the polypeptide.

6. The method of claim 5 , wherein the polypeptide lacks a transmembrane domain that spans a cell membrane.

7. The method of claim 5 , further comprising isolating the polypeptide.

8. The method of claim 5 , wherein the glycoprotein is selected from the group consisting of: lactoferrin, whey, and immunoglobulin.

9. A composition comprising:

(i) a recombinant polypeptide comprising a sequence at least 90% identical to or SEQ ID NO:5, wherein said polypeptide can cleave high mannose, complex, and hybrid N-glycans from a glycoprotein and wherein the polypeptide lacks a transmembrane domain; and

(ii) a glycoprotein, wherein the glycoprotein comprises a high mannose, complex, or hybrid N-glycan.

10. The composition of claim 9 , wherein the glycoprotein is selected from the group consisting of: lactoferrin, whey, and immunoglobulin.

11. The composition of claim 9 , wherein the N-glycan comprises core fucosylation, terminal fucosylation, or terminal sialylation.

12. The composition of claim 9 , wherein the polypeptide is a transmembrane protein in a cell membrane protein in a cell.

13. The composition of claim 9 , wherein the glycoprotein comprises a high mannose N-glycan.

14. The method of claim 4 , wherein the glycoprotein comprises a high mannose N-glycan.

15. The method of claim 4 , wherein the glycoprotein comprises a complex N-glycan.

16. The method of claim 4 , wherein the glycoprotein comprises a hybrid N-glycan.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2014
From: GARRIDO, DANIEL; GERMAN, J. BRUCE; LEBRILLA, CARLITO B.; MILLS, DAVID A.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 034522/0124 →
Continuity (2)
Provisional Application 61598593 · Feb 14, 2012
Related Publication 20150110771A1 · Apr 23, 2015